Cargando…

Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics

Sphingosine 1-phosphate (S1P) is a bioactive lipid that is formed by the phosphorylation of sphingosine and catalysed by sphingosine kinase 1 (SK1) or sphingosine kinase 2 (SK2). Sphingosine kinases play a fundamental role in many signaling pathways associated with cancer, suggesting that proteins b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evangelisti, Cecilia, Evangelisti, Camilla, Teti, Gabriella, Chiarini, Francesca, Falconi, Mirella, Melchionda, Fraia, Pession, Andrea, Bertaina, Alice, Locatelli, Franco, McCubrey, James A., Beak, Dong Jae, Bittman, Robert, Pyne, Susan, Pyne, Nigel J., Martelli, Alberto M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202168/ https://www.ncbi.nlm.nih.gov/pubmed/25226616

Ejemplares similares

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
por: Bressanin, Daniela, et al.
Publicado: (2012)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias
por: Martelli, Alberto M., et al.
Publicado: (2020)

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
por: Lonetti, Annalisa, et al.
Publicado: (2016)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
por: Lonetti, Annalisa, et al.
Publicado: (2015)

The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
por: Martelli, Alberto M., et al.
Publicado: (2010)

Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
por: Martelli, Alberto M., et al.
Publicado: (2022)

The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia
por: Chiarini, Francesca, et al.
Publicado: (2020)

Structure–Activity Relationships and Molecular Modeling of Sphingosine Kinase Inhibitors
por: Baek, Dong Jae, et al.
Publicado: (2013)

The Roles of Sphingosine Kinase 1 and 2 in Regulating the Metabolome and Survival of Prostate Cancer Cells
por: Tonelli, Francesca, et al.
Publicado: (2013)

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
por: Martelli, Alberto M., et al.
Publicado: (2012)

Sphingosine kinase 2 and multiple myeloma
por: Pyne, Nigel J., et al.
Publicado: (2017)

Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells
por: Pyne, Nigel J., et al.
Publicado: (2017)

Therapeutic targeting of CK2 in acute and chronic leukemias
por: Buontempo, F, et al.
Publicado: (2018)

Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers
por: Pyne, Susan, et al.
Publicado: (2012)

Selectivity and Specificity of Sphingosine 1-Phosphate Receptor Ligands: “Off-Targets” or Complex Pharmacology?
por: Pyne, Nigel J., et al.
Publicado: (2011)

Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
por: Martelli, Alberto M., et al.
Publicado: (2023)

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines
por: Ultimo, Simona, et al.
Publicado: (2017)

FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells
por: Tonelli, Francesca, et al.
Publicado: (2010)

Does the Sphingosine 1-Phosphate Receptor-1 Provide a Better or Worse Prognostic Outcome for Breast Cancer Patients?
por: Pyne, Nigel J., et al.
Publicado: (2018)

MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia
por: Astolfi, Annalisa, et al.
Publicado: (2013)

Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells
por: McNaughton, Melissa, et al.
Publicado: (2016)

Negative pressure treatment for necrotizing fasciitis after chemotherapy
por: Melchionda, Fraia, et al.
Publicado: (2011)

Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)
por: Pession, Andrea, et al.
Publicado: (2008)

Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer
por: Ohotski, J, et al.
Publicado: (2012)

Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor negative breast cancer
por: Ohotski, J, et al.
Publicado: (2012)

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
por: Chiarini, Francesca, et al.
Publicado: (2012)

A new model for regulation of sphingosine kinase 1 translocation to the plasma membrane in breast cancer cells
por: Brown, Ryan D.R., et al.
Publicado: (2021)

The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response
por: Martelli, Alberto M., et al.
Publicado: (2019)

The Cutting Edge: The Role of mTOR Signaling in Laminopathies
por: Chiarini, Francesca, et al.
Publicado: (2019)

Implication of Cellular Senescence in Osteoarthritis: A Study on Equine Synovial Fluid Mesenchymal Stromal Cells
por: Teti, Gabriella, et al.
Publicado: (2023)

Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension
por: MacRitchie, Neil, et al.
Publicado: (2016)

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2013)

Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse
por: Greig, Fiona H., et al.
Publicado: (2019)

B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?
por: Ratti, Stefano, et al.
Publicado: (2020)

The sphingosine 1-phosphate receptor 2 is shed in exosomes from breast cancer cells and is N-terminally processed to a short constitutively active form that promotes extracellular signal regulated kinase activation and DNA synthesis in fibroblasts
por: El Buri, Ashref, et al.
Publicado: (2018)

Sphingosine Kinase 1 Regulates the Survival of Breast Cancer Stem Cells and Non-stem Breast Cancer Cells by Suppression of STAT1
por: Hii, Ling-Wei, et al.
Publicado: (2020)

Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model
por: Mazzotti, Eleonora, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5q2d64la94b9ks6sifjo0pe6c3